SGC-CBP30 (CAS: 1613695-14-9) is a small molecule inhibitor that has attracted significant attention from researchers for its potential therapeutic applications. This compound was first identified by scientists at the Structural Genomics Consortium in Toronto and has since undergone several studies to investigate its mechanism of action, safety profile, and efficacy. In this article, we will explore the chemical properties, health benefits, potential effects, product mechanism, safety, side effects, and dosing information of SGC-CBP30 and provide a conclusion about its current status as a therapeutic agent.
Chemical Properties: SGC-CBP30 is a synthetic small molecule with the chemical name N-[3-(6-acetamidopyridin-3-yl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)-3,4-dihydroisoquinoline-2-carboxamide. Its molecular formula is C28H32N6O2, and its molecular weight is 496.6 g/mol. It is a white to off-white powder that is soluble in DMSO and ethanol.
Top Ten Keywords from Google:
Synonyms:
Health Benefits: SGC-CBP30 has been studied primarily for its potential use in cancer treatment. Studies have shown that it inhibits the growth of various types of cancer cells, including breast, lung, colon, and prostate cancer cells. SGC-CBP30 works by targeting a protein called CBP/p300, which plays an important role in regulating gene expression. By inhibiting CBP/p300, SGC-CBP30 can affect transcriptional regulation and histone acetylation, leading to anti-tumor effects and the induction of apoptosis.
Potential Effects: In addition to its potential use in cancer treatment, SGC-CBP30 has also shown promise in treating other diseases related to epigenetics, such as Alzheimer's disease and muscular dystrophy. Studies have shown that SGC-CBP30 can improve cognitive function in mouse models of Alzheimer's disease and promote muscle regeneration in a mouse model of muscular dystrophy.
Product Mechanism: SGC-CBP30 exerts its effects by selectively inhibiting the activity of CBP/p300, which are transcriptional coactivators that regulate gene expression. CBP/p300 play a crucial role in histone acetylation, which is a post-translational modification of chromatin that affects gene expression. By inhibiting CBP/p300, SGC-CBP30 can decrease the levels of acetylated histones, leading to changes in gene expression and the induction of apoptosis in cancer cells.
Safety: The safety profile of SGC-CBP30 has not yet been established in humans. Preclinical studies have shown promising results, but further research is needed to evaluate its toxicity and potential side effects.
Side Effects: The potential side effects of SGC-CBP30 are currently unknown. However, some studies have suggested that inhibiting CBP/p300 could affect the expression of genes involved in neuronal development and function, which could lead to cognitive impairment. Further studies are needed to evaluate the long-term safety of this compound.
Dosing Information: The optimal dose of SGC-CBP30 has not yet been established. In preclinical studies, doses ranging from 0.5 to 50 mg/kg have been used. More research is needed to determine the appropriate dose range for clinical use.
Conclusion: SGC-CBP30 is a promising small molecule inhibitor with potential applications in cancer treatment and other diseases related to epigenetics. Its ability to selectively inhibit the activity of CBP/p300 makes it an attractive candidate for further study. However, its safety profile in humans needs to be established before it can be recommended for clinical use. With further research, SGC-CBP30 could potentially become an important tool in the fight against cancer and other epigenetic-related diseases
